From: Wnt signaling in colorectal cancer: pathogenic role and therapeutic target
No. | Full official name | Intervention mechanism | References |
---|---|---|---|
1 | lncRNA HOTAIR | Regulate the expression level of miR-203a-3p and the activity of the Wnt/β-catenin signaling pathway to regulate the progression and resistance of CRC | [248] |
2 | SM08502 | Effectively inhibit CDC-like kinase (CLK) activity to reduce Wnt pathway signal transduction and gene expression | [249] |
3 | IWR-1 | Inhibition of Wnt/β-catenin pathway and survivin expression to inhibit tumor metastasis potential | [250] |
4 | Pimozide | Decreased expression of β-catenin and Wnt target genes c-Myc, cyclin D1, Axin 2, and survivin | [251] |
5 | lncRNA Linc00675 | Overexpression inhibits the proliferation, invasion and migration of CRC cells | [252] |
6 | XAV939 | Overcome resistance to 5-FU in CRC cells carrying short APCs, thereby inhibiting the Wnt/β-catenin signaling cascade | [253] |
7 | USP22 | Mediates CRC cell chemoresistance through Wnt/β-catenin pathway, and reducing USP22 in CRC cells will reduce chemoresistance | [254] |
8 | GPR125 | Overexpression inhibits the transcriptional activity of β-catenin and down-regulates the expression levels of Wnt downstream proteins Axin2, c-Myc, cylinD1 and lef-1, and its effect on the inactivation of Wnt/β-catenin signaling pathway may inhibit the formation of CRC Key link | [255] |
9 | DK419 | Inhibit Wnt/β-catenin signal transduction, change cell oxygen consumption rate and induce the production of pAMPK, inhibit the growth of CRC tumor cells | [256] |
10 | BC029135 | Inhibit CRC invasion and inactivate Wnt/β-catenin signaling | [125] |
11 | ETC-1922159 | Can block all Wnt secretion and activity | [257] |
12 | γ-secretase inhibitor (GSI) PF-03084014 | Significantly reduced active β-catenin | [258] |
13 | Niclosamide | Inhibit Wnt/β-catenin pathway activation, down-regulate Dvl2, and reduce downstream β-catenin signal transduction | [174] |
14 | MiR-148a | Overexpression inhibits the expression of stem cell markers, inhibits spheroid formation, invasion and migration, induces apoptosis and inhibits the downstream target WNT10b is miR-148a | [178] |
15 | AGR2 | Activating CaMKII to antagonize classic Wnt/β-catenin signaling may be a potential therapeutic target for inhibiting CRC metastasis | [259] |
16 | PARP1 inhibitors | PARP1 can act on the Wnt signaling pathway, affecting the binding affinity of β-catenin/transcription factor 4 (TCF4), and PARP1 inhibition significantly reduces the number of metastases of ATMIN knockdown cancer cells | [260] |
17 | Novel stemona alkaloid analogues compound 3 | Effectively inhibit various CRC cells, including 5-fluorouracil resistant CRC cells, and reduce the protein level of β-catenin | [261] |
18 | AZD6244 | MEK1/2 inhibitor AZD6244 may mediate the upregulation of Wnt pathway | [177] |
19 | Bispecific antibodies (BiAbs) | CD133 is a surface marker of CSC, and the application of targeted therapy against CD133 has achieved initial promising results | [262] |
20 | NO donor agent | NO is considered to be an important mediator in many signaling pathways in CRC, such as Wnt/β-catenin, NO donor agents deliver high levels of NO to the tumor site | [263] |
21 | mesalazine | Treatment of colorectal cancer (CRC) cells with mesalazine leads to increased expression of the adhesion molecule Mu-protocadherin (MUCDHL) and is related to the isolation of β-catenin on the plasma membrane and the inhibition of its transcriptional activity | [264] |
22 | 36–077, a PIK3C3/VPS34 inhibitor, | Can inhibit GSK-3β/Wnt/β-catenin signaling to inhibit CSC population | [265] |
23 | Aspirin | Inhibits the formation and action of COX-2 and PGE-2, and also acetylates COX-2 to produce “aspirin-triggered” lipoxin (ATL), which is a new class of anti-inflammatory/anti-tumor compounds | [266] |